Galderma Group N (SW:GALD) — Stock Price
Galderma Group N (SW:GALD) is currently trading at CHF175.95 CHF, down 2.98% today. Over the past 52 weeks, shares have ranged between CHF130.60 and CHF185.80. This page tracks Galderma Group N's live share price on the SW exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Galderma Group N (GALD) market capitalisation.
Galderma Group N (GALD) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Galderma Group N's daily closing share price and trading volume on the SW exchange over the past year, giving a clear view of recent price momentum and liquidity.
Galderma Group N Income Statement — Revenue, Profit & Earnings by Year
Galderma Group N's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | CHF4.32 Billion | CHF4.44 Billion | CHF3.67 Billion | CHF3.59 Billion | CHF3.12 Billion |
| Cost of Revenue | CHF1.43 Billion | CHF1.35 Billion | CHF1.11 Billion | CHF1.14 Billion | CHF945.26 Million |
| Gross Profit | CHF2.90 Billion | CHF3.08 Billion | CHF2.56 Billion | CHF2.45 Billion | CHF2.18 Billion |
| Research & Development | CHF201.81 Million | CHF260.00 Million | CHF257.82 Million | CHF301.71 Million | CHF313.23 Million |
| SG&A | — | CHF543.00 Million | CHF467.00 Million | CHF439.30 Million | CHF353.70 Million |
| Total Operating Expenses | CHF2.19 Billion | CHF2.44 Billion | CHF2.04 Billion | CHF2.12 Billion | CHF1.88 Billion |
| Operating Income | CHF708.40 Million | CHF645.00 Million | CHF517.71 Million | CHF327.01 Million | CHF300.89 Million |
| EBITDA | CHF976.65 Million | CHF959.00 Million | CHF690.44 Million | CHF592.24 Million | CHF476.06 Million |
| EBIT | CHF708.40 Million | CHF666.00 Million | CHF511.21 Million | CHF327.01 Million | CHF247.95 Million |
| Interest Expense | CHF157.79 Million | CHF317.04 Million | CHF503.96 Million | CHF378.21 Million | CHF320.82 Million |
| Income Before Tax | CHF529.85 Million | CHF310.00 Million | CHF9.80 Million | CHF-49.57 Million | CHF-72.87 Million |
| Income Tax Expense | CHF21.59 Million | CHF79.00 Million | CHF61.20 Million | CHF42.98 Million | CHF4.11 Million |
| Net Income | CHF509.09 Million | CHF231.00 Million | CHF-48.11 Million | CHF-94.07 Million | CHF-141.07 Million |
Galderma Group N Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Galderma Group N's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Total Assets | CHF12.62 Billion | CHF10.49 Billion | CHF11.49 Billion | CHF11.45 Billion |
| Total Current Assets | CHF1.84 Billion | CHF1.36 Billion | CHF1.39 Billion | CHF1.38 Billion |
| Cash & Equivalents | CHF175.00 Million | CHF127.20 Million | — | — |
| Short-term Investments | CHF158.59 Million | CHF107.06 Million | CHF185.04K | CHF2.46 Million |
| Net Receivables | CHF910.00 Million | CHF531.23 Million | CHF731.46 Million | CHF666.51 Million |
| Inventory | CHF403.00 Million | CHF353.00 Million | CHF409.22 Million | CHF315.99 Million |
| Property, Plant & Equipment | CHF577.00 Million | CHF529.20 Million | CHF400.80 Million | — |
| Goodwill | CHF5.13 Billion | CHF4.32 Billion | CHF4.74 Billion | CHF4.68 Billion |
| Total Liabilities | CHF4.83 Billion | CHF5.97 Billion | CHF7.35 Billion | CHF7.31 Billion |
| Total Current Liabilities | CHF1.53 Billion | CHF1.32 Billion | CHF1.81 Billion | CHF1.69 Billion |
| Long-term Debt | CHF2.64 Billion | CHF4.75 Billion | CHF5.25 Billion | — |
| Net Debt | CHF2.30 Billion | CHF3.82 Billion | CHF5.02 Billion | CHF4.92 Billion |
| Total Stockholder Equity | CHF7.79 Billion | CHF4.52 Billion | CHF4.13 Billion | CHF4.14 Billion |
| Retained Earnings | CHF5.68 Billion | CHF-757.64 Million | CHF-780.50 Million | CHF-678.81 Million |
Galderma Group N Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Galderma Group N generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Operating Cash Flow | CHF429.77 Million | CHF148.64 Million | CHF106.30 Million | CHF178.92 Million |
| Capital Expenditures | CHF275.00 Million | CHF102.02 Million | CHF152.33 Million | CHF117.03 Million |
| Free Cash Flow | CHF213.00 Million | CHF37.09 Million | CHF-46.03 Million | CHF61.90 Million |
| Investing Cash Flow | CHF-287.10 Million | CHF-156.10 Million | CHF-70.48 Million | CHF-487.76 Million |
| Financing Cash Flow | CHF-51.08 Million | CHF127.34 Million | CHF-68.86 Million | CHF290.01 Million |
| Dividends Paid | — | — | — | — |
| Stock-Based Compensation | CHF68.00 Million | CHF0.00 | — | — |
| Depreciation | CHF293.00 Million | CHF248.39 Million | CHF277.70 Million | CHF253.10 Million |
| Change in Cash | CHF53.06 Million | CHF-13.90 Million | CHF-42.82 Million | CHF259.22 Million |
Galderma Group N Earnings History — EPS Actual vs. Analyst Estimates
Track Galderma Group N's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Jul 23, 2026 | — | — | — |
| Mar 05, 2026 | — | — | — |
| Jul 24, 2025 | 0.82 | 0.00 | — |
| Mar 05, 2025 | 0.77 | 0.84 | -8.33% |
| Jul 25, 2024 | 0.55 | 1.12 | -50.89% |